Acarbose, an α-glucosidase inhibitor, delays absorption of carbohydrate in the gut, thereby
lowering postprandial glucose levels. Safety data on this drug have been gathered in a …

Importance The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-like
peptide 1 receptor agonist, on weight loss maintenance in people with overweight or …

… Two-sided 95% CIs and corresponding P values were calculated for all statistical analysis
results. Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc). Efficacy …

Schizophrenia is characterized by cognitive impairments and widespread structural brain
abnormalities. Brain structure-cognition associations have been extensively studied in …

Objective: Liraglutide, a once-daily human glucagon-like peptide-1 analog, induced clinically
meaningful weight loss in a phase 2 study in obese individuals without diabetes. The …

OBJECTIVE Obesity is an important risk factor for type 2 diabetes. Weight loss in patients with
type 2 diabetes is associated with improved glycemic control and reduced cardiovascular …

… P values were calculated from Fisher's exact test. ADA, American Diabetes Association;
ACE, American College of Endocrinology; IDF, International Diabetes Federation. …

… of rimonabant than with placebo (p=0·02 for 5 mg, p<0·0001 for 20 mg; table 2 and figure 2B).
… function (p=0·002) and self-esteem domains (p=0·004) and in the total IWQoL-Lite score (…

A plethora of treatment options exist for cancer therapeutics, but many are limited by side
effects and either intrinsic or acquired resistance. The need for more effective targeted cancer …

The M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) regimen was used to treat
25 patients with transitional cell carcinoma of the urothelial tract. Treatment consisted of …